Orexin Receptor Antagonists for Major Depressive Disorder: Perspectives From a Systematic Review and Meta-Analysis

Why It Matters

The results introduce orexin pathway modulation as a credible therapeutic avenue, expanding options for patients who fail to respond to conventional antidepressants and antipsychotics.

Key Takeaways

• Pooled QXR‑ANTs reduced HDRS17/MADRS scores (SMD –0.16).
• Remission odds rose 52% versus placebo.
• Seltorexant 20 mg/day drove efficacy signal.
• Filorexant and tebideutorexant showed no benefit.
• No rise in somnolence or dizziness reported.

Pulse Analysis

Depression remains a leading cause of disability, with roughly half of patients experiencing inadequate response to at least two standard antidepressants. This therapeutic gap has spurred interest in alternative neurobiological targets, and the orexin system—known for regulating arousal, reward, and stress pathways—has emerged as a promising candidate. By influencing hypothalamic‑pituitary‑adrenal axis activity, orexin receptor antagonists could address core mood dysregulation while also improving sleep, a frequent comorbidity in major depressive disorder.

The meta‑analysis pooled data from six double‑blind, placebo‑controlled trials, revealing a modest but consistent reduction in depressive symptom severity across pooled QXR‑ANTs. Notably, seltorexant 20 mg/day produced the most robust effect, achieving a standardized mean difference of –0.36 on the HDRS17 and a marginally significant increase in remission rates. In contrast, higher seltorexant dosing and other agents such as filorexant and tebideutorexant failed to demonstrate superiority, underscoring the importance of receptor selectivity and dose optimization. Importantly, the safety profile remained favorable, with no significant uptick in somnolence, dizziness, or abnormal dreams, alleviating concerns about excessive sedation in a depressive cohort.

These findings have immediate implications for drug development and clinical practice. Selective OX2R antagonism could be positioned as an adjunctive therapy for patients with treatment‑resistant depression, potentially complementing existing antidepressants without adding substantial adverse effects. However, the modest effect size and limited trial numbers warrant cautious interpretation. Larger, phase‑III studies are needed to confirm efficacy, explore long‑term safety, and identify patient subgroups most likely to benefit. As the field moves toward precision psychiatry, integrating orexin‑targeted agents may broaden the therapeutic toolkit and improve outcomes for a population that has historically faced limited options.